Avidity to present poster on precision
cardiology candidate at American Heart Association (AHA) Scientific
Sessions 2024 taking place November
16-18, 2024
Volume 11 of investor and analyst event series
will be available via webcast November 12,
2024, at 8:00 a.m. ET
SAN
DIEGO, Oct. 31, 2024 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
the company will share new development candidates from its
precision cardiology portfolio and provide a first look at its
next-generation technology innovations.
Video Webcast Information
The company is hosting Volume 11 of its investor and analyst event
series on November 12, 2024,
beginning at 8:00 a.m. ET. The
virtual event will be available via a live video webcast and can be
accessed here or from the "Events and Presentations" page
in the "Investors" section of Avidity's website. A replay of the
webcast will be archived on Avidity's website following the
event.
Avidity will be presenting a poster on a lead precision
cardiology candidate at the American Heart Association (AHA)
Scientific Sessions 2024 on November 16,
2024, at 11:40 a.m. CT in
Chicago, Illinois.
POSTER PRESENTATION
November 16, 2024: 11:40 a.m. - 11:45 a.m. CT
- Novel Precision Cardiology Treatment for
PRKAG2 Cardiomyopathy, a Subset of Patients with
Wolff-Parkinson-White Syndrome
The poster will be available on the publications page of
Avidity's website at https://www.aviditybiosciences.com.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCs™). Avidity is
revolutionizing the field of RNA with its proprietary AOCs, which
are designed to combine the specificity of monoclonal antibodies
with the precision of oligonucleotide therapies to address targets
and diseases previously unreachable with existing RNA therapies.
Utilizing its proprietary AOC platform, Avidity demonstrated the
first-ever successful targeted delivery of RNA into muscle and is
leading the field with clinical development programs for three rare
muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular
dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
Avidity is broadening the reach of AOCs with its advancing and
expanding pipeline including programs in cardiology and immunology
through internal discovery efforts and key partnerships. Avidity is
headquartered in San Diego, CA. For more information about our AOC
platform, clinical development pipeline and people, please
visit www.aviditybiosciences.com and engage with us
on LinkedIn and X.
Investor Contact:
Mike MacLean
(619) 837-5014
investors@aviditybio.com
Media Contact:
Navjot Rai
(619) 837-5016
media@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-host-investor-and-analyst-event-focused-on-precision-cardiology-candidates-and-first-look-at-next-generation-technology-innovations-on-november-12-2024-302292234.html
SOURCE Avidity Biosciences, Inc.